CN116159110A - 一种化湿清斑复方中药在治疗贝赫切特病中的新用途 - Google Patents
一种化湿清斑复方中药在治疗贝赫切特病中的新用途 Download PDFInfo
- Publication number
- CN116159110A CN116159110A CN202310279000.9A CN202310279000A CN116159110A CN 116159110 A CN116159110 A CN 116159110A CN 202310279000 A CN202310279000 A CN 202310279000A CN 116159110 A CN116159110 A CN 116159110A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- clearing
- spots
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 208000009137 Behcet syndrome Diseases 0.000 title claims abstract description 34
- 150000001875 compounds Chemical class 0.000 title claims abstract description 28
- 208000027496 Behcet disease Diseases 0.000 title abstract description 9
- 238000011282 treatment Methods 0.000 claims abstract description 41
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 230000005484 gravity Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 44
- 229940079593 drug Drugs 0.000 abstract description 10
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 7
- 240000003915 Lophatherum gracile Species 0.000 abstract description 7
- 241000304432 Sedum sarmentosum Species 0.000 abstract description 7
- 235000013399 edible fruits Nutrition 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 5
- 244000111489 Gardenia augusta Species 0.000 abstract description 4
- 235000018958 Gardenia augusta Nutrition 0.000 abstract description 4
- 240000000774 Cunila origanoides Species 0.000 abstract description 3
- 235000018274 Cunila origanoides Nutrition 0.000 abstract description 3
- 235000014866 Dictamnus albus Nutrition 0.000 abstract description 3
- 235000011477 liquorice Nutrition 0.000 abstract description 3
- 239000003053 toxin Substances 0.000 abstract description 3
- 231100000765 toxin Toxicity 0.000 abstract description 3
- 240000007164 Salvia officinalis Species 0.000 abstract description 2
- 240000004534 Scutellaria baicalensis Species 0.000 abstract description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract description 2
- 240000009022 Smilax rotundifolia Species 0.000 abstract description 2
- 235000003205 Smilax rotundifolia Nutrition 0.000 abstract description 2
- 235000005412 red sage Nutrition 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 230000001737 promoting effect Effects 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 17
- 208000025865 Ulcer Diseases 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 16
- 231100000397 ulcer Toxicity 0.000 description 15
- 208000007117 Oral Ulcer Diseases 0.000 description 13
- 208000002399 aphthous stomatitis Diseases 0.000 description 13
- 230000000144 pharmacologic effect Effects 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 210000002216 heart Anatomy 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 210000003905 vulva Anatomy 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 7
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 235000019658 bitter taste Nutrition 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 229960003433 thalidomide Drugs 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 241001106477 Paeoniaceae Species 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 241000405414 Rehmannia Species 0.000 description 5
- 208000020670 canker sore Diseases 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 4
- 241000207929 Scutellaria Species 0.000 description 4
- 208000032023 Signs and Symptoms Diseases 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000002398 materia medica Substances 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 3
- 235000017491 Bambusa tulda Nutrition 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010019909 Hernia Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 244000082204 Phyllostachys viridis Species 0.000 description 3
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 239000011425 bamboo Substances 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000916 dilatatory effect Effects 0.000 description 3
- -1 flavonoid compounds Chemical class 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 240000005717 Dioscorea alata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 240000005001 Paeonia suffruticosa Species 0.000 description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 241000222640 Polyporus Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 2
- 229940015301 baicalein Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 208000022306 Cerebral injury Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000025599 Heat Stress disease Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000745390 Lophatherum Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010028034 Mouth ulceration Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 201000001949 Retinal Vasculitis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241001404789 Smilax glabra Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229930182485 cyanogenic glycoside Natural products 0.000 description 1
- 150000008142 cyanogenic glycosides Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000013441 ocular lesion Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种化湿清斑复方中药在治疗贝赫切特病中的新用途,属于中药制剂新用途技术领域。由10~20份土茯苓、5~15份白鲜皮、6~12份垂盆草、6~12份黄芩、6~12份地肤子、3~8份生地黄、3~8份丹皮、3~8份丹参、5~12份赤芍、3~8份白芍、3~8份淡竹叶、5~12份山栀和5~8份甘草制得的化湿清斑复方中药可应用于治疗贝赫切特病。化湿清斑复方中药是将这些药物组合使得各药物功效产生协同作用,能够有效治疗贝赫切特病,副作用小。该复方中药具有清热化湿,解毒消斑的功能,治疗贝赫切特病的疗程短、见效快、治愈后不易复发,而且价格低廉、不易复发、使用方便。
Description
技术领域
本发明属于中药制剂新用途技术领域,具体是涉及一种化湿清斑复方中药在治疗贝赫切特病中的新用途。
背景技术
贝赫切特病(Behcet’s disease,BD)是一种慢性、多系统、炎症性疾病,以黏膜、眼部、肌肉骨骼、血管、中枢神经系统和胃肠道炎症反复发作为主要特征,若累及消化道、心血管、中枢神经系统,则提示预后不佳。病因主要包括遗传因素、感染因素和免疫因素。发病机制仍不清楚,目前认为具有一定遗传易感性的个体在感染等因素的作用下,引起固有免疫和适应性免疫应答异常(包括T细胞稳态改变),最终导致慢性炎症。BD以血管炎为主要病理,病理特征为可累及大、中、小血管的血管炎。特征性临床表现为典型三联征,即口腔阿弗他溃疡(aphthous ulcer)、阴部溃疡及无菌性葡萄膜炎(aseptic uveitis),造成BD患者病程痛苦、生活质量低。BD可分为血管型、胃肠型和神经型,其中血管型常导致较高的致死率和致残率。BD的治疗目前没有标准的治疗方案,根据患者器官受累程度、性别和年龄的不同而变化。其治疗方案以综合治疗为主,以抗感染、调节免疫功能、减轻疼痛及促进愈合为目的。糖皮质激素、硫唑嘌呤和环磷酰胺被推荐为血管型贝赫切特病的一线治疗药物,但均不能完全控制病情,症状易反复,且副作用大,长远治疗效果不佳。
由于西药治疗副作用大,贝赫切特病患者又反复出现口腔溃疡、阴部溃疡等,严重影响生活质量。因此,人们对有效治疗贝赫切特病的中药药物存在极大的需求,我国用于治疗贝赫切特病引起的口腔溃疡、阴部溃疡的中药以外用为主,仍缺乏口服中药。
发明内容
本发明的目的在于提供一种有效治疗贝赫切特病的药物,所要解决的技术问题是通过药理和临床研究在已知的复方中药中遴选可供临床应用的治疗贝赫切特病的有效药物。
一种化湿清斑复方中药,组方的有效成分由如下重量份的中药原料制得:
本发明提出了一种该化湿清斑复方中药的新用途,即将上述复方中药应用于贝赫切特病的治疗中。
上述化湿清斑复方中药组方中,各原料药的药效如下:
土茯苓,别称刺猪苓、过山龙、仙余粮、禹余粮等,始载于《本草经集注》,百合科植物光叶菝葜的干燥根状茎,味甘、淡,性平,归肝、胃、脾经,具有解毒、除湿、通利关节的功效。现代药理学研究表明,土茯苓含有多种活性成分,如黄酮、苯丙素、甾体、有机酸、挥发油类等成分,在抗炎、镇痛、免疫系统、心血管系统和肿瘤等方面均有明显的作用。
白鲜皮,别名白藓皮等,首载于《神农本草经》,属芸香科植物白鲜的干燥根皮。性味苦,寒,归脾、胃、膀胱经。具有清热燥湿,祛风解毒的功效。《纲目》载:“白鲜皮,气寒善行,味苦性燥,为诸黄风痹要药,世医止施之疮科,浅矣”。主治湿热疮毒,黄水淋漓,湿疹,风疹,疥癣疮癞,风湿热痹。现代药理毒理研究表明白鲜皮具有抗病原微生物、抗内毒素、抗炎和免疫抑制作用以及保肝作用。
垂盆草,药性甘、淡,凉,归肝、胆、小肠经。具有利湿退黄,清热解毒的功效。《本草纲目拾遗·卷五》:载“消痈肿,治湿郁水肿”“治诸毒及汤烙伤,疗痈,虫蛇螫咬”。现代药理研究表明,本品主要含黄酮类成分,还含三萜、甾醇、生物碱、氰苷、多糖等成分,主要有保肝、抗菌、调节免疫、抗肿瘤等作用。
黄芩,别名山茶根,是唇形科黄芩属多年生草本植物,其以根入药,味苦、性寒,归肺、胆、胃、大肠经,有清热燥湿、泻火解毒、止血、安胎等功效。现代药理研究表明,此药具有解热,镇静,降血压,降血糖,降血脂,利胆,保肝,抗氧化等作用;黄芩的主要活性成分黄芩素等能抑制线粒体脂质过氧化和卵磷脂质体代谢,对抗过氧化氢引起的细胞损伤,对心肌缺血再灌注有保护作用。
地肤子,性辛、苦,寒,归肾、膀胱经,具有清热利湿,祛风止痒的功效。《滇南本草》:载其“利膀胱小便积热,洗皮肤之风,疗妇人诸经客热,清利胎热,湿热带下”。现代药理研究发现,地肤子主要含皂苷类成分、甾类成分、三萜类成分等,其中成分三萜皂苷为主要生物活性成分,其具有显著的抗炎作用;地肤子水浸剂对多种皮肤真菌和伤寒杆菌有抑制作用;水提取物有抑制单核巨噬系统的吞噬功能及迟发性超敏反应的作用。
生地黄,性味甘、苦,寒,归心、肝、肾经,为玄参科植物地黄的干燥块根。具有清热凉血、养阴生津的功效。《本经》:载“主折跌绝筋,伤中,逐血痹,填骨髓,长肌肉,作汤除寒热积聚,除痹。”现代药理研究表明,生地黄主要成分地黄苷、地黄低聚糖可增强体液免疫和细胞免疫功能,还具有抗胃溃疡、促进造血、止血、降压、抗骨质疏松、对脑缺血及脑损伤及神经衰弱具有保护等作用。
丹皮,别名:粉丹皮,洛阳花等,性苦、辛,微寒,归心、肝、肾经。具有清热凉血,活血化瘀的功效。《本经》:“主寒热,中风瘈疭、痉、惊痫邪气,除症坚瘀血留舍肠胃,安五脏,疗痈疮。”现代药理研究表明,本品有抗菌、抗炎、镇痛、抗肿瘤、保肝等多种药理作用。
丹参,性苦,微寒,归心、肝经。具有活血去瘀、止痛的功效。古云“一味丹参散,功同四物汤”,实为凉血活血、去瘀生新之品。《本草纲目·卷十二》载:“活血,通心包络,治疝痛。”现代药理研究表明,本品能抗心律失常扩张冠脉,增加冠脉血流量,调节血脂,抗动脉粥样硬化,能改善微循环,保护心肌,抑制免疫反应等作用。
赤芍,性苦,微寒,归肝经。具有清热凉血,活血化瘀的功效。《名医别录》:“通顺血脉,缓中,散恶血,逐贼血,去水气,利膀胱大小肠,消痈肿,时行寒热,中恶腹痛,腰痛。”现代药理分析,赤芍含有芍药甙、安息香酸、挥发油、树脂、糖类、淀粉等,对痢疾杆菌、葡萄球菌有抑制作用,并有镇痛、镇静和抗惊厥的作用。
白芍,味苦、酸,性微寒,归肝、脾经。具有养血调经,敛阴止汗,柔肝止痛,平抑肝阳的功效。《本经》:"主邪气腹痛,除血痹,破坚积,治寒热疝瘕,止痛,利小便,益气。”现代药理研究发现,白芍的主要有效成分是芍药甙,具有改善心肌血注,扩张血管,抑制血小板聚集,镇静、镇痛抗炎、抗溃疡等多种作用。
淡竹叶,别名竹叶卷心,药性甘、淡,寒,归心、胃、小肠经。具有清热除烦、利尿的功效。《本草纲目·卷十六》:“去烦热,利小便,清心。”现代药理研究表明,竹叶中含有大量的黄酮类化合物和生物活性多糖及其它有效成分,竹叶中所含的功能因子主要是黄酮糖苷和香豆素类内酯,竹叶提取物具有优良的抗自由基、抗氧化、抗衰老、降血脂和血胆固醇的作用。
山栀,又名栀子、山栀子,为茜草科植物山栀的果实,性寒味苦,入心经、肝经、肺经、胃经,有清热,泻火,凉血之效。《纲目》:“治吐血、衄血、血痢、下血、血淋,损伤瘀血,及伤寒劳复,热厥头痛,疝气,汤火伤。”现代研究表明栀子有保肝、利胆,并且对胃液分泌和胃肠蠕动有影响,山栀还有有降低血压、降低心肌收缩力、减慢心率、扩张血管以及抗炎等效果,并对软组织损伤有一定治疗作用。
甘草,性甘、平,归心、肺、脾、胃经。具有益气补中,祛痰止咳,解毒,缓急止痛,缓和药性的功效。《名医别录》载甘草:“温中下气,烦满短气,伤脏咳嗽,止渴,通经脉,利气血,解百药毒。”现代药理研究表明,甘草含有多种化学成分,主要成分有甘草酸、甘草甙等,甘草剂有抗炎和抗变态反应,甘草有肾上腺皮质激素样作用;甘草制剂能促进胃部粘液形成和分泌,甘草的黄酮具有消炎、解痉和抗酸作用。
中医认为,贝赫切特病由湿热毒邪壅盛所致,治宜清热利湿、解毒消斑为法。方中土茯苓、白鲜皮清热化湿解毒,为君药;垂盆草清利湿热解毒,黄芩清热燥湿解毒,地肤子清热利水止痒,三药性寒凉,可助君药清热利湿解毒,共为臣药。君臣相配,恰和湿热壅盛之病机。丹皮、丹参、赤芍清热凉血,并能活血散瘀消斑,以防热与血结,助君臣清热之功。又恐湿热伤及营阴,故用清热养阴之生地黄、养血敛阴之白芍,顾护营阴;淡竹叶、山栀子清心解毒除烦,淡竹叶甘寒淡渗,能导湿热下行,从小便而去;生甘草清热解毒,共为佐使药。正如吴鞠通所云“徒清热则湿不退,徒祛湿则热愈炽”唯清利兼施,切中病机,故诸药相伍,共成清热利湿、解毒消斑之功。治疗贝赫切特病的疗程短、见效快、治愈后不易复发,而且价格低廉、不易复发、使用方便。
本发明提出的化湿清斑复方中药选择土茯苓、白鲜皮、垂盆草、黄芩、地肤子、生地黄、丹皮、丹参、赤芍、白芍、淡竹叶、山栀和甘草中药配伍,将这些药物组合使得各药物功效产生协同作用,能够有效治疗贝赫切特病,副作用小。
作为本发明的化湿清斑复方中药在贝赫切特病中的新用途的优选技术方案,其有效成分由如下重量份的中药原料制得:
作为本发明的化湿清斑复方中药在治疗贝赫切特病中的新用途的优选技术方案,化湿清斑复方中药的制备方法,步骤如下:
1)、将13味药材洗净,按比例混合后每次加6~8倍重量的70%乙醇回流2-3次,每次1-2小时,合并每次的提取液,过滤并浓缩,得到60℃时比重为1.0~1.2的流浸膏;
2)、采用现有常规制备工艺,制成凝胶剂、凝胶膏剂、软膏剂、片剂、胶囊剂、颗粒剂、滴丸剂、口服液、丸剂、糖浆剂、分散片或泡腾片中的任一种剂型。
附图说明
图1是两组患者治疗前后口腔溃疡发作频次比较。
图2是两组患者治疗前后口腔溃疡总间歇时间比较。
图3是两组患者治疗前后ESR比较。
图4是两组患者治疗前后CRP比较。
具体实施方式
以下结合附图和实施例对本发明的一种化湿清斑复方中药在治疗贝赫切特病中的新用途作出进一步的详述。
实施例1
1)、将土茯苓15g、白鲜皮12g、垂盆草10g、黄芩8g、地肤子8g、生地黄6g、丹皮6g、丹参6g、赤芍8g、白芍6g、淡竹叶6g、山栀8g、甘草6g洗净,混合后每次加7倍重量的70%乙醇回流2次,每次2小时,合并2次提取液,过滤并浓缩,得到60℃时比重为1.15的流浸膏。
2)、采用常规制备工艺,制成颗粒剂。
实施例2
1)、将土茯苓18g、白鲜皮15g、垂盆草12g、黄芩10g、地肤子11g、生地黄7g、丹皮8g、丹参8g、赤芍10g、白芍6g、淡竹叶8g、山栀10g、甘草8g洗净,混合后每次加6倍重量的70%乙醇回流2次,每次1小时,合并2次提取液,过滤并浓缩,得到60℃时比重为1.2的流浸膏。
2)、采用常规制备工艺,制成软膏剂、胶囊剂或者泡腾片
一、临床试验
1、病例选择
选择2021年1月至2022年1月期间安徽中医药大学第一附属医院风湿科门诊或住院患者40例。
(1)诊断标准
采用1989年国际BD研究小组制定的国际分类标准。有反复口腔溃疡并有其他4项中2项以上者,可诊断为本病。
①反复口腔溃疡:由医生观察到或者患者诉说有口腔溃疡,1年内反复发作至少3次。
②反复外阴溃疡:由医生观察到或者患者诉说外阴部有溃疡或瘢痕。
③眼病变:前葡萄膜炎、后葡萄膜炎或裂隙灯检查时玻璃体内有细胞出现或由眼科医生观察到视网膜血管炎。
④皮肤病变:由医生观察到或者患者诉说的结节性红斑、假性毛囊炎或丘疹性脓疱样,或未服用糖皮质激素的非青春期患者出现痤疮样结节。
⑤针刺试验阳性。
(2)纳入标准
①符合BD西医诊断标准;②轻型BD患者,主要表现为皮肤黏膜病变;③年龄:18-65岁;④知情同意参加本次试验。
(3)排除标准
①不符合上述纳入标准;②治疗过程中合用了激素及沙利度胺以外的免疫抑制剂的患者;③符合沙利度胺禁忌症者;④出现眼睛、消化道、神经、血管等重要脏器累及的重型BD患者;⑤合并有其他严重的原发性疾病(心、脑、肺、肝、肾、血液等系统疾病)、精神病患者;⑥妊娠及哺乳期患者。
(4)剔除标准
①病情控制不佳,出现严重的并发症者;②治疗过程中出现严重不良反应,不能继续接受治疗者;③未按规定服药,无法判定疗效者;④受试者自行退出临床试验者。
2、治疗方法
纳入的40例BD患者随机分为对照组20例与治疗组20例,两组一般资料无显著差异,具有可比性。
对照组:口服沙利度胺片(常州制药厂有限公司,批号:H32026130),50mg,qd。
治疗组:沙利度胺片(50mg,qd)+本发明上述实施例1制备所得的复方中药颗粒剂(1袋,tid)。
两组疗程均为3个月。
3、观察指标
1)疗效评价标准
参照《中药新药临床研究指导原则》:①临床控制:口腔、外阴、眼、皮肤等症状、体征消失,实验室各项检查指标恢复正常;②显效:大部分症状、体征消失,实验室检查指标恢复正常;③有效:部分症状、体征消失或主症明显改善,实验室检查指标有所改善;④无效:症状、体征及实验室各项检查指标无变化或加重。治疗组20例患者中,临床控制5例、显效8例、有效6例,总有效率95.00%;对照组20例患者中,临床控制4例、显效5例、有效8例,总有效率85.00%;治疗组疗效优于对照组,差异有统计学意义(P<0.05)。具体结果见表1。
表1两组患者治疗前后临床疗效比较
2)口腔溃疡发作情况
记录治疗前后3个月内口腔溃疡发作频次及口腔溃疡总间歇时间。两组治疗前后组内比较,口腔溃疡发作频次、口腔溃疡总间歇时间差异均有统计学意义(P<0.05);两组治疗后组间比较,口腔溃疡发作频次、溃疡总间歇时间差异均有统计学意义(P<0.05),治疗组在改善口腔溃疡发作方面疗效优于对照组。具体结果见图1、图2。
3)炎症指标ESR、CRP
检测治疗前后两组患者ESR、CRP水平。两组治疗后ESR、CRP水平均较治疗前明显下降(P<0.05);两组治疗后组间比较,CRP差异无统计学意义(P>0.05),治疗组ESR水平低于对照组,差异有统计学意义(P<0.05)。具体结果见图3、图4。
二、疗效调查
为检验本发明中药复方制剂的治疗效果,选取30例BD患者给予本发明上述实施例1制备所得的复方中药颗粒剂治疗;其中男性13例,女性17例,年龄18~65岁,平均年龄36岁。病程0.5~10年。临床表现主要为口腔溃疡、外阴溃疡、皮肤红斑等。
疗效评定标准:
(1)临床控制:口腔、外阴、眼、皮肤等症状、体征消失,实验室各项检查指标恢复正常;
(2)显效:大部分症状、体征消失,实验室检查指标恢复正常;
(3)有效:部分症状、体征消失或主症明显改善,实验室检查指标有所改善;
(4)无效:症状、体征及实验室各项检查指标无变化或加重。
疗效评定结果:
30例贝赫切特病患者服用本发明的复方中药颗粒剂2个疗程后,临床控制10例、显效12例、有效6例,总有效率93.3%,总有效率十分显著。
三、典型病例
病例1
余某,女,35岁,反复口腔及外阴部溃疡5年余。患者5年前出现口腔及外阴溃疡,皮疹瘙痒,反复复发,易心烦,汗出,四肢沉重,纳一般,夜寐不安,小便黄,大便黏;在外院完善相关检查后确诊为“贝赫切特病”;一直服用“沙利度胺”口服治疗,症状未见明显改善;后患者为求中药治疗就诊于我科门诊。查体:神清,精神可,口腔黏膜溃破,双上臂可见散在局部皮疹,伴瘙痒不适;舌红,苔黄腻,脉濡数;辨证为湿热蕴结证,予以本发明复方中药颗粒剂治疗2个疗程后,口腔及外阴溃疡症状消失,皮肤瘙痒症状明显缓解,心烦不寐明显改善,纳寐可,二便调。
病例2
胡某,女,52岁,反复口腔溃疡,外阴溃疡2年。刻下症:口腔溃疡,疲倦乏力,双目红赤疼痛,口苦咽干,心烦易怒,大便黏滞不畅,舌质红、有瘀点,边有齿痕,苔黄腻,脉濡数。曾在某外院治疗,诊断为“白塞氏病”,予以甲泼尼龙、羟氯喹,上述症状反复发作,疗效不佳;服本发明复方中药颗粒剂2个疗程后,口腔及外阴溃疡消失,疲倦乏力、大便黏滞不畅等症状明显好转,诸症减轻。
病例3
汤某,女,31岁,反复口腔及外阴部溃疡6年余。患者6年前反复出现口腔及外阴溃疡,偶有皮疹,口干口苦,纳可,夜寐欠安,小便黄,大便调。在外院完善相关检查后确诊为“贝赫切特病”,予以“沙利度胺”口服治疗,症状仍反复。患者为求进一步诊疗就诊于门诊。查体:神清,精神可,口腔黏膜溃破,外阴未查,全身皮肤可见散在皮疹;舌红,苔黄腻,脉滑数。辨证为湿热蕴结证,予本发明复方中药颗粒剂治疗8周后,口腔及外阴溃疡复发次数明显减少,皮肤瘙痒症状明显缓解,无明显口干口苦,纳寐可,二便调。
以上内容仅仅是对本发明的构思所作的举例和说明,所属本技术领域的技术人员对所描述的具体实施例做各种各样的修改或补充或采用类似的方式替代,只要不偏离发明的构思或者超越本权利要求书所定义的范围,均应属于本发明的保护范围。
Claims (3)
3.如权利要求1或2所述的新用途,其特征在于,所述化湿清斑复方中药的步骤如下:
1)、将13味药材洗净,按比例混合后每次加6~8倍重量的70%乙醇回流2-3次,每次1-2小时,合并每次的提取液,过滤并浓缩,得到60℃时比重为1.0~1.2的流浸膏;
2)、采用现有常规制备工艺,制成凝胶剂、凝胶膏剂、软膏剂、片剂、胶囊剂、颗粒剂、滴丸剂、口服液、丸剂、糖浆剂、分散片或泡腾片中的任一种剂型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310279000.9A CN116159110B (zh) | 2023-03-21 | 2023-03-21 | 一种化湿清斑复方中药在治疗贝赫切特病中的新用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310279000.9A CN116159110B (zh) | 2023-03-21 | 2023-03-21 | 一种化湿清斑复方中药在治疗贝赫切特病中的新用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116159110A true CN116159110A (zh) | 2023-05-26 |
CN116159110B CN116159110B (zh) | 2024-01-26 |
Family
ID=86411549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310279000.9A Active CN116159110B (zh) | 2023-03-21 | 2023-03-21 | 一种化湿清斑复方中药在治疗贝赫切特病中的新用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116159110B (zh) |
-
2023
- 2023-03-21 CN CN202310279000.9A patent/CN116159110B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN116159110B (zh) | 2024-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111991535B (zh) | 一种具有治疗幽门螺杆菌相关性胃炎功能的中药提取物及其制备方法和应用 | |
CN116159110B (zh) | 一种化湿清斑复方中药在治疗贝赫切特病中的新用途 | |
CN103191322A (zh) | 一种治疗重症急性胰腺炎的中药 | |
CN113768978B (zh) | 一种治疗溃疡性结肠炎的彝药组合物及其制备方法 | |
CN102430008B (zh) | 治疗胃肠疾病中药组合物及其制备方法 | |
CN102430009B (zh) | 治疗胃肠疾病中药组合物及其制备方法 | |
CN111228367B (zh) | 一种治疗小儿过敏性紫癜的中药外用洗剂及其制备方法 | |
CN107007702A (zh) | 一种治疗骨关节病的中药组合物及其制剂 | |
CN103495120B (zh) | 一种治疗盆腔炎的中药组合物及其制备方法 | |
CN105726787A (zh) | 一种治疗溃疡性结肠炎的中药灌肠剂及其制备方法 | |
CN105435162B (zh) | 一种治疗过敏性鼻炎的中药组合物、制备方法及中药制剂 | |
CN108888723A (zh) | 一种润肠通便的组合物及其制备方法与应用 | |
CN112206279B (zh) | 一种治疗室性心律失常的中药组合物及其制备方法和应用 | |
CN107007697A (zh) | 一种治疗盆腔炎或前列腺炎的中药组合物及其制剂 | |
CN116763880B (zh) | 一种治疗功能性消化不良伴消瘦的中药组合物、制剂及其应用 | |
CN115054644B (zh) | 一种治疗糖尿病足的中药组合物及其制备方法 | |
CN116350741B (zh) | 一种治疗糖尿病胃轻瘫的中药组合物及其制备方法 | |
CN102416088B (zh) | 治疗胃肠疾病中药组合物及其制备方法 | |
CN102430075B (zh) | 治疗胃肠疾病中药组合物及其制备方法 | |
CN106421612A (zh) | 抗幽门螺旋杆菌胃病的药物组合物 | |
CN105168397A (zh) | 一种防治肾病的药物组合物 | |
CN111643650A (zh) | 一种治疗痛经的中药配方 | |
CN117752758A (zh) | 一种治疗痞满的中药组合物及其应用 | |
CN118178519A (zh) | 一种用于治疗便秘的中药组合物及其工艺 | |
CN111617222A (zh) | 一种治疗腹泻型肠易激综合征的中药组合物及其中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |